Drug Discovery and Evaluation: Methods in Clinical Pharmacology

Drug Discovery and Evaluation: Methods in Clinical Pharmacology

2
药理学

售价：

发货周期：预计8-10周发货

作者

Hock, Franz J.();Gralinski, Michael R.()

出版社

Springer Berlin Heidelberg

出版时间

2020年07月27日

装帧

ＩＳＢＮ

9783319688633

复制

页码

1200

语种

英文

版次

0002,2020

综合评分

暂无评分

图书详情
目次
买家须知
书评（0）
权威书评（0）

图书简介

This is the second edition of a well-received book in the series ?Drug Discovery and Evaluation? The completely revised new edition of the volume reflects the current state of the art in Clinical Pharmacology.Drug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined. As these processes can be divided up stepwise we have designed a book series "Drug Discovery and Evaluation" in the form of arecommendationdocument. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: ?Methods in Clinical Pharmacology".For the 2ndedition of this volume, the chapters have been revised and completely updated. A large number of assays were added. New chapters were included, such as pain, addiction, gene therapy, orphan diseases.

Section A Introduction:1 General Introduction;- Section B Human Studies in Clinical Pharmacology: 2 Methodologies of Safety Assessment in Clinical Pharmacology;- 3 Pharmacodynamic Evaluation: Cardiovascular Methodologies;- 4 Pharmacodynamic Evaluation: Pulmonary Methodologies;- 5 Pharmacodynamic Evaluation: CNS Methodologies;- 6 Pharmacodynamic Evaluation: Pain Methodologies;- 7 Pharmacodynamic Evaluation: Drug Dependency and Addiction;- 8 Pharmacodynamic Evaluation: Ocular Pharmacology;- 9 Pharmacodynamic Evaluation: Acoustic Pharmacology (Tinnitus);- 10 Pharmacodynamic Evaluation: Diabetic Methodologies;- 11 Pharmacodynamic Evaluation: Gastroenterology;- 12 Pharmacodynamic Evaluation: Endocrinology;- 13 Pharmacodynamic Evaluation: Inflammation/Immunology;- 14 Pharmacodynamic Evaluation: Dermatology;- 15 Pharmacodynamic Evaluation: Infectious Diseases;- 16 Pharmacodynamic Evaluation: Oncology;- 17 Pharmacodynamic Evaluation: Gentherapy;- 18 Pharmacodynamic Evaluation: Orphan Diseases;- 19 Clinical Studies in Infants (Pediatric Pharmacology);- 20 Clinical Studies in Geriatric Population;- 21 Personalized Medicine;- 22 Non-invasive Methodology (NMR);- 23 Traditional Chinese Medicine; - 24 Pharmacodynamic Evaluation: Herbal Medicine;- 25 Nanotechnology in Medicine;- 26 Methodologies of PD Assessment Scales;- 27 Methodologies of Pharmacodynamic Assessment;- 28 Pharmacodynamic Drug-Drug Interaction.Section C Clinical Pharmacokinetics: 29 Dose Finding in Single Dose Studies by Allometric Scaling;- 30 Multiple Dose Studies;- 31 Dose Linearity and Proportionality;- 32 Effects of Food Intake;- 33 Special Populations: Profiling the Effect of Obesity on Drug Disposition;- 34 Special Population: Renal Impairment;- 35 Special Population: Hepatic Impairment; - 36 Special Population: Protein Binding Aspects;- 37 The Human ADME Study;- 38 Synthesis of Radiolabeled Compounds for Clinical Studies;- 39 Drug-Drug Interaction Studies;- 40 In Vitro/In Vivo Correlation for Drug-Drug Interaction;- 41 Specific Studies for Formulation Development;- 42 Absolute and Relative Bioavailability;- 43 Bioequivalence;- 44 Population Pharmacokinetics in Clinical Pharmacology;- 45 Bioanalysis of Clinical Studies;- 46 Biomarker Definition and Validation During Drug Development;- 47 Toxicokinetics and Safety Ratios;- 48 In Vitro/In Vivo Correlation for Transporters;- 49 Relevance of Transporters in Clinical Studies;- 50 Specificities for Oncology Studies;- 51 Pharmacogenomics in and its Influence on Pharmacokinetics;- 52 PK/PD Approaches.Section D Regulations: 53 Regulatory Guidance:EMA, FDA, ICH;- 54 Development of Regulations for Submitting Pharmacogenomic Data to Authorities;- 55 Pharmacogenomic-Guided Drug Development;- 56 Clinical Quality Management System.

Trade Policy 买家须知